8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 23, 2010

BIOANALYTICAL SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Indiana	0-23357	35-1345024
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

2701 KENT AVENUE WEST LAFAYETTE, INDIANA	47906-1382
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (765) 463-4527

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

On December 23, 2010, Bioanalytical Systems, Inc. (the "Company") executed an Amendment (“Amendment”) to its line of credit agreement with Entrepreneur Growth Capital LLC.  As part of the Amendment, the maturity date for the line of credit was extended to January 31, 2013 and the line of credit will automatically renew each year thereafter until either party gives the required notice of termination pursuant to the terms of the agreement.  The Amendment reduced the minimum tangible net worth covenant requirement to $8.5 million and waived all non-compliances with this covenant through the date of the Amendment.

The foregoing discussion of the Amendment is entirely qualified by reference to the text of the Amendment, which is attached as Exhibit 10.1 to this report, and incorporated herein by this reference.

 Item 9.01.Exhibits.

(d)	Exhibits
10.1	Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Entrepreneur Growth Capital LLC, executed December 23, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Bioanalytical Systems, Inc.
Date: December 30, 2010	By:	/s/ Michael R. Cox
		Michael R. Cox
		Vice President, Finance and Administration, Chief Financial Officer and Treasurer

Exhibit Index

Exhibit No.	Description
10.1	Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Entrepreneur Growth Capital LLC, executed December 23, 2010.

EX-10.1

AMENDMENT TO
LOAN AND SECURITY AGREEMENT

This Amendment (“Amendment”) to Loan and Security Agreement is dated December 23, 2010 and entered into by and between Entrepreneur Growth Capital LLC (“Lender”), and Bioanalytical Systems, Inc. (“Borrower”).

WHEREAS, Lender and Borrower have entered into a Loan and Security Agreement, as may have been amended from time to time (the “Loan Agreement”) dated on or about January 11, 2010; and

WHEREAS, Borrower has requested that Lender waive compliance and to also permanently re-set the tangible net worth covenant for future periods; and

WHEREAS, Lender has agreed to waive Borrower’s compliance to meet the tangible net worth covenant and to also permanently re-set the tangible net worth covenant for future periods.

NOW, THEREFORE, in consideration of the mutual conditions and agreements set forth in the Loan Agreement and this Amendment, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, hereby agree as follows:

I.      DEFINITIONS

A.          Definitions. Capitalized terms used in this Amendment, to the extent not otherwise defined herein, shall have the same meanings as in the Loan Agreement, as amended hereby.

II.      AMENDMENTS AND AGREEMENTS

A.          Amendment to Section 4.15, Net Worth Covenant. Section 4.15 shall be, and the same is hereby amended by re-stating the tangible net worth covenant to be not less than $8,500,000.00.

B.           Waiver. Lender hereby waives Borrower's compliance with the tangible net worth covenant for all periods up to and including the date of this Amendment.

C.           Amendment to Section 7.1, Term. Section 7.1 shall be, and the same is hereby amended by restating the first sentence of Section 7.1 to modify the definition of Initial Term to be the last day of the month, three (3) years from the original date of the Loan Agreement (i.e., January 31, 2013). Accordingly, the first sentence of Section 7.1 shall be restated to read as follows:

Page 1 of 3

“This Agreement shall become effective upon acceptance by Lender and shall continue in full force and effect for a term ending on the last business day of the month, three (3) years from the date hereof (the “Initial Term”) and shall automatically renew from year to year thereafter (each, a “Renewal Term”) until terminated pursuant to the terms hereof.”

III.      MISCELLANEOUS

A.           Conditions. The effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent (unless specifically waived in writing by Lender):

(i) there shall have occurred no material adverse change in the business, operations, financial conditions, profits or prospects, or in the Collateral of the Borrower;

(ii) Borrower shall have executed and delivered such other documents and instruments as Lender may require;

(iii) Borrower shall have paid Lender a fee in the amount of $1,000.00 as consideration for the consent and execution of the Amendment, plus a documentation fee in the amount of $500.00, which fees shall automatically be charged to Borrower’s loan account upon the execution of this Amendment.

(iv) all corporate proceedings taken in connection with the transactions contemplated by this Amendment and all documents, instruments and other legal matters incident thereto shall be satisfactory to Lender and its legal counsel.

B.           Ratification. The terms and provisions set forth in this Amendment shall modify and supersede all inconsistent terms and provisions set forth in the Loan Agreement and, except as expressly modified and superseded by this Amendment, the terms and provisions of the Loan Agreement, are ratified and confirmed and shall continue in full force and effect.

C.           Corporate Action. The execution, delivery and performance of this Amendment have been authorized by all requisite corporate action on the part of Borrower and will not violate the Articles of Incorporation or Bylaws of Borrower.

D.           Severability. Any provision of this Amendment held by a court of competent jurisdiction to be invalid or unenforceable shall not impair or invalidate the remainder of this Amendment and the effect thereof shall be confined to the provision so held to be invalid or unenforceable.

E.           Successors and Assigns. This Amendment is binding upon and shall inure to the benefit of Lender and Borrower and their respective successors and assigns.

Page 2 of 3

F.           Counterparts. This Amendment may be executed in one or more counterparts, each of which when so executed shall be deemed to be an original, but all of which when taken together shall constitute one and the same instrument. An executed facsimile of this Amendment shall be deemed to be a valid and binding agreement between the parties hereto.

IN WITNESS WHEREOF, the parties have executed this Amendment on the date first above written.

ENTREPRENEUR GROWTH CAPITAL LLC, as Lender
By:	/s/ Charles L. Bert
Name:	Charles L. Bert
Title:	Vice President,
BIOANALYTICAL SYSTEMS, INC., as Borrower
By:	/s/ Michael R. Cox
Name:	Michael R. Cox
Title:	Vice President - Finance

Page 3 of 3